<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2025-3150</article-id><article-id custom-type="edn" pub-id-type="custom">MITYPR</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-3150</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>POINT OF VIEW</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ТОЧКА ЗРЕНИЯ</subject></subj-group></article-categories><title-group><article-title>Diabetic cardiomyopathy: merely a complication or a distinct understudied disease?</article-title><trans-title-group xml:lang="ru"><trans-title>Диабетическая кардиомиопатия: исключительно осложнение или отдельное малоизученное заболевание?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8820-9436</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Марданов</surname><given-names>Б. У.</given-names></name><name name-style="western" xml:lang="en"><surname>Mardanov</surname><given-names>B. U.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Марданов Баходир Умаркулович </p><p>Москва </p></bio><bio xml:lang="en"><p>Bakhodir U. Mardanov </p><p>Moscow </p></bio><email xlink:type="simple">mb_sky@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7131-8049</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мамедов</surname><given-names>М. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Mamedov</surname><given-names>M. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мамедов Мехман Ниязи оглы </p><p>Москва </p></bio><bio xml:lang="en"><p>Mehman N. Mamedov </p><p>Moscow </p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center for Therapy and Preventive Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>22</day><month>08</month><year>2025</year></pub-date><volume>21</volume><issue>3</issue><fpage>298</fpage><lpage>306</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Mardanov B.U., Mamedov M.N., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Марданов Б.У., Мамедов М.Н.</copyright-holder><copyright-holder xml:lang="en">Mardanov B.U., Mamedov M.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/3150">https://www.rpcardio.online/jour/article/view/3150</self-uri><abstract><p>Since the 1970s, researchers have investigated a specific disorder of myocardial structure and function in diabetes mellitus (DM) — diabetic cardiomyopathy (DC) – whose primary clinical manifestation is heart failure (HF). Numerous studies demonstrate a high risk of HF in patients with type 2 diabetes mellitus (T2DM), alongside worsened prognosis when these conditions coexist. For instance, the Kaiser Permanente population study demonstrated a 3- to 4-fold higher HF risk in T2DM patients under 75 years compared to non-diabetic individuals. Despite accumulated research, DCM remains classified by many experts as a complication of DM rather than a distinct entity, fueling ongoing discussion. At the same time, ongoing studies increasingly reveal characteristic disorders of heart function with pathophysiological features, suggesting that DCM may constitute a separate condition occurring within the diabetic context. To date, there are no generally accepted clinical guidelines for DCM diagnosis and management, and therefore there is a need for standardized diagnostic criteria to identify high-risk populations. The review analyzes current literature data on terminology, etiology, pathogenesis, and treatment. Systematisation of existing knowledge and clear diagnostic criteria would facilitate greater focus on novel treatment strategies.</p></abstract><trans-abstract xml:lang="ru"><p>Начиная с 70-х годов прошлого столетия предметом изучения специалистов и ученых является специфическое нарушение структуры и функции миокарда при сахарном диабете (СД) — диабетическая кардиомиопатия (ДК), основным клиническим проявлением которой является сердечная недостаточность (СН). Многочисленные исследования демонстрируют высокий риск развития СН у больных сахарным диабетом 2 типа (СД2), а также ухудшение прогноза вышеуказанных заболеваний при сопряженном течении. Так, в популяционном исследовании Kaiser Permanente у пациентов с СД2 моложе 75 лет риск СН был в 3-4 раза выше, чем у пациентов без диабета. Несмотря на накопленный опыт в изучении патологии, ДК множеством специалистов рассматривается как осложнение СД, а не как отдельное состояние, и является предметом споров и дискуссий. В то же время, проводимые исследования все чаще выявляют характерные нарушения функции сердца с особенностями патофизиологии, что дает основание говорить о, возможно, отдельном состоянии, протекающем на фоне СД. К настоящему времени нет общепринятых клинических руководств по диагностике и лечению ДК, в связи с чем существует потребность определения четких и ясных диагностических критериев ДК, что жизненно важно для выявления групп высокого риска развития данной кардиомиопатии. В обзорной статье анализируются данные литературы по изучаемой проблеме, касающиеся терминологии, этиологии, патогенеза и лечения. Систематизация имеющихся знаний, четкая формулировка критериев постановки диагноза позволили бы больше сосредоточиться на поиске новых терапевтических методов.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>диабетическая кардиомиопатия</kwd><kwd>сердечная недостаточность</kwd><kwd>автономная нейропатия</kwd><kwd>инсулинорезистентность</kwd><kwd>эндотелиальная дисфункция</kwd><kwd>сахароснижающая терапия</kwd><kwd>ингибиторы натрий-глюкозного котранспортера 2 типа</kwd></kwd-group><kwd-group xml:lang="en"><kwd>diabetic cardiomyopathy</kwd><kwd>heart failure</kwd><kwd>cardiac autonomic neuropathy</kwd><kwd>insulin resistance</kwd><kwd>endothelial dysfunction</kwd><kwd>hypoglycemic therapy</kwd><kwd>sodium-glucose cotransporter 2 inhibitors</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Караваев П.Г., Веклич А.С., Козиолова Н.А. Диабетическая кардиомиопатия: особенности сердечно-сосудистого ремоделирования. Российский кардиологический журнал. 2019;24(11):42-7. DOI:10.15829/1560-4071-2019-11-42-47.</mixed-citation><mixed-citation xml:lang="en">Karavaev PG, Veklich AS, Koziolova NA. Diabetic cardiomyopathy: features of cardiovascular remodeling. Russian Journal of Cardiology. 2019;24(11):42-7. (In Russ.) DOI:10.15829/1560-4071-2019-11-42-47.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">MacDonald MR, Petrie MC, Varyani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29(11):1377-85. DOI:10.1093/eurheartj/ehn153.</mixed-citation><mixed-citation xml:lang="en">MacDonald MR, Petrie MC, Varyani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29(11):1377-85. DOI:10.1093/eurheartj/ehn153.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Khan H, Anker SD, Januzzi JL Jr, et al. Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease. J Card Fail. 2019;25(2):78-86. DOI:10.1016/j.cardfail.2018.10.015.</mixed-citation><mixed-citation xml:lang="en">Khan H, Anker SD, Januzzi JL Jr, et al. Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease. J Card Fail. 2019;25(2):78-86. DOI:10.1016/j.cardfail.2018.10.015.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001;24(9):1614-9. DOI:10.2337/diacare.24.9.1614.</mixed-citation><mixed-citation xml:lang="en">Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001;24(9):1614-9. DOI:10.2337/diacare.24.9.1614.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Сорокина А.Г., Орлова Я.А. Современный взгляд на механизмы развития диабетической кардиомиопатии и возможности их коррекции. Российский кардиологический журнал. 2019;24(11):142-7. DOI:10.15829/1560-4071-2019-11-142-147.</mixed-citation><mixed-citation xml:lang="en">Sorokina AG, Orlova YaA. A modern view on the mechanisms of diabetic cardiomyopathy development and the its modification options. Russian Journal of Cardiology. 2019;24(11):142-7 (In Russ.) DOI:10.15829/1560-4071-2019-11-142-147.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Кобалава Ж.Д., Ешниязов Н.Б., Медовщиков В.В. и др. Сахарный диабет 2-го типа и сердечная недостаточность: инновационные возможности управления прогнозом. Кардиология. 2019;59(4):76-87. DOI:10.18087/cardio.2019.4.10253.</mixed-citation><mixed-citation xml:lang="en">Kobalava ZhD. Eshniyazov NB, Medovshchikov VV, et al. Type 2 diabetes mellitus and heart failure: innovative possibilities for prognosis management. Kardiologiia. 2019;59(4):76-87. (In Russ.) DOI:10.18087/cardio.2019.4.10253.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Aneja A, Tang WH, Bansilal S, et al. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med. 2008;121(9):748-57. DOI: 10.1016/j.amjmed.2008.03.046.</mixed-citation><mixed-citation xml:lang="en">Aneja A, Tang WH, Bansilal S, et al. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med. 2008;121(9):748-57. DOI: 10.1016/j.amjmed.2008.03.046.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lorenzo-Almorós A, Cepeda-Rodrigo JM, Lorenzo Ó. Diabetic cardiomyopathy. Rev Clin Esp. 2020:S0014-2565(20)30025-4. DOI:10.1016/j.rce.2019.10.013.</mixed-citation><mixed-citation xml:lang="en">Lorenzo-Almorós A, Cepeda-Rodrigo JM, Lorenzo Ó. Diabetic cardiomyopathy. Rev Clin Esp. 2020:S0014-2565(20)30025-4. DOI:10.1016/j.rce.2019.10.013.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Marcinkiewicz A, Ostrowski S, Drzewoski J, et al. Can the onset of heart failure be delayed by treating diabetic cardiomyopathy? Diabetol Metab Syndr. 2017;9:21. DOI:10.1186/s13098-017-0219-z.</mixed-citation><mixed-citation xml:lang="en">Marcinkiewicz A, Ostrowski S, Drzewoski J, et al. Can the onset of heart failure be delayed by treating diabetic cardiomyopathy? Diabetol Metab Syndr. 2017;9:21. DOI:10.1186/s13098-017-0219-z.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Багрий А.Э., Супрун Е.В., Михайличенко Е.С., Голодников И.А. Хроническая сердечная недостаточность и сахарный диабет 2 типа: состояние проблемы. Российский кардиологический журнал. 2020;25(4):3858. DOI:10.15829/1560-4071-2020-3858.</mixed-citation><mixed-citation xml:lang="en">Bagriy AE, Suprun YV, Mykhailichenko IS, et al. Chronic heart failure and type 2 diabetes: state of the problem. Russian Journal of Cardiology. 2020;25(4):3858. (In Russ.) DOI:10.15829/1560-4071-2020-3858.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Park JJ. Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes. Diabetes Metab J. 2021;45(2):146-57. DOI:10.4093/dmj.2020.0282.</mixed-citation><mixed-citation xml:lang="en">Park JJ. Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes. Diabetes Metab J. 2021;45(2):146-57. DOI:10.4093/dmj.2020.0282.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Bertoni AG, Tsai A, Kasper EK, Brancati FL. Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. Diabetes Care. 2003;26(10):2791-5. DOI:10.2337/diacare.26.10.2791.</mixed-citation><mixed-citation xml:lang="en">Bertoni AG, Tsai A, Kasper EK, Brancati FL. Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. Diabetes Care. 2003;26(10):2791-5. DOI:10.2337/diacare.26.10.2791.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Maack C, Lehrke M, Backs J, et al. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. Eur Heart J. 2018;39(48):4243-54. DOI:10.1093/eurheartj/ehy596.</mixed-citation><mixed-citation xml:lang="en">Maack C, Lehrke M, Backs J, et al. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. Eur Heart J. 2018;39(48):4243-54. DOI:10.1093/eurheartj/ehy596.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Li X, Wu F, Günther S, Looso M, et al. Inhibition of fatty acid oxidation enables heart regeneration in adult mice. Nature. 2023;622(7983):619-26. DOI:10.1038/s41586-023-06585-5.</mixed-citation><mixed-citation xml:lang="en">Li X, Wu F, Günther S, Looso M, et al. Inhibition of fatty acid oxidation enables heart regeneration in adult mice. Nature. 2023;622(7983):619-26. DOI:10.1038/s41586-023-06585-5.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Lambert R, Srodulski S, Peng X, et al. Intracellular Na+ Concentration ([Na+]i) Is Elevated in Diabetic Hearts Due to Enhanced Na+-Glucose Cotransport. J Am Heart Assoc. 2015;4(9):e002183. DOI:10.1161/JAHA.115.002183.</mixed-citation><mixed-citation xml:lang="en">Lambert R, Srodulski S, Peng X, et al. Intracellular Na+ Concentration ([Na+]i) Is Elevated in Diabetic Hearts Due to Enhanced Na+-Glucose Cotransport. J Am Heart Assoc. 2015;4(9):e002183. DOI:10.1161/JAHA.115.002183.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Nielsen R, Jorsal A, Iversen P, et al. Heart failure patients with prediabetes and newly diagnosed diabetes display abnormalities in myocardial metabolism. J Nucl Cardiol. 2018;25(1):169-76. DOI:10.1007/s12350-016-0622-0.</mixed-citation><mixed-citation xml:lang="en">Nielsen R, Jorsal A, Iversen P, et al. Heart failure patients with prediabetes and newly diagnosed diabetes display abnormalities in myocardial metabolism. J Nucl Cardiol. 2018;25(1):169-76. DOI:10.1007/s12350-016-0622-0.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Obokata M, Reddy YNV, Pislaru SV, et al. Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Circulation. 2017;136(1):6-19. DOI:10.1161/CIRCULATIONAHA.116.026807.</mixed-citation><mixed-citation xml:lang="en">Obokata M, Reddy YNV, Pislaru SV, et al. Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Circulation. 2017;136(1):6-19. DOI:10.1161/CIRCULATIONAHA.116.026807.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018;17(1):121. DOI:10.1186/s12933-018-0763-3.</mixed-citation><mixed-citation xml:lang="en">Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018;17(1):121. DOI:10.1186/s12933-018-0763-3.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">De Keulenaer GW, Brutsaert DL. Systolic and diastolic heart failure are overlapping phenotypes within the heart failure spectrum. Circulation. 2011;123(18):1996- 2004; discussion 2005. DOI:10.1161/CIRCULATIONAHA.110.981431.</mixed-citation><mixed-citation xml:lang="en">De Keulenaer GW, Brutsaert DL. Systolic and diastolic heart failure are overlapping phenotypes within the heart failure spectrum. Circulation. 2011;123(18):1996- 2004; discussion 2005. DOI:10.1161/CIRCULATIONAHA.110.981431.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Нуждина Е.В., Давыдова Е.В. Автономная кардиальная нейропатия и ремоделирование миокарда левого желудочка у пациентов с сахарным диабетом и сопутствующими болезнями системы кровообращения и почек. Профилактическая медицина. 2020;23(1):127-34. DOI:10.17116/profmed202023011127.</mixed-citation><mixed-citation xml:lang="en">Nuzhdina EV, Davydova EV. Cardiac autonomic neuropathy and left ventricular myocardial remodeling in patients with diabetes mellitus and concomitant diseases of the circulatory system and kidneys. Russian Journal of Preventive Medicine. 2020;23(1):127-34. (In Russ.) DOI:10.17116/profmed202023011127.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Jani Y, Kamberi A, Xhunga S, et al. The influence of type 2 diabetes and gender on ventricular repolarization dispersion in patients with sub-clinic left ventricular diastolic dysfunction. Am J Cardiovasc Dis. 2015;5(4):155-66.</mixed-citation><mixed-citation xml:lang="en">Jani Y, Kamberi A, Xhunga S, et al. The influence of type 2 diabetes and gender on ventricular repolarization dispersion in patients with sub-clinic left ventricular diastolic dysfunction. Am J Cardiovasc Dis. 2015;5(4):155-66.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Silverii GA, Toncelli L, Casatori L, et al. Assessment of left ventricular global longitudinal strain in patients with type 2 diabetes: Relationship with microvascular damage and glycemic control. Nutr Metab Cardiovasc Dis. 2022;32(4):994-1000. DOI:10.1016/j.numecd.2022.01.014.</mixed-citation><mixed-citation xml:lang="en">Silverii GA, Toncelli L, Casatori L, et al. Assessment of left ventricular global longitudinal strain in patients with type 2 diabetes: Relationship with microvascular damage and glycemic control. Nutr Metab Cardiovasc Dis. 2022;32(4):994-1000. DOI:10.1016/j.numecd.2022.01.014.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Stanton AM, Vaduganathan M, Chang LS, et al. Asymptomatic diabetic cardiomyopathy: An underrecognized entity in type 2 diabetes. Curr Diabetes Rep. 2021;21(10):41. DOI:10.1007/s11892-021-01407-2.</mixed-citation><mixed-citation xml:lang="en">Stanton AM, Vaduganathan M, Chang LS, et al. Asymptomatic diabetic cardiomyopathy: An underrecognized entity in type 2 diabetes. Curr Diabetes Rep. 2021;21(10):41. DOI:10.1007/s11892-021-01407-2.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Seferovic PM, Paulus WJ. Clinical diabetic cardiomyopathy: A two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015;36(27):1718-27, 1727a-1727c. DOI:10.1093/eurheartj/ehv134.</mixed-citation><mixed-citation xml:lang="en">Seferovic PM, Paulus WJ. Clinical diabetic cardiomyopathy: A two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015;36(27):1718-27, 1727a-1727c. DOI:10.1093/eurheartj/ehv134.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Liu X, Yang ZG, Gao Y, et al. Left ventricular subclinical myocardial dysfunction in uncomplicated type 2 diabetes mellitus is associated with impaired myocardial perfusion: a contrast-enhanced cardiovascular magnetic resonance study. Cardiovasc Diabetol. 2018;17(1):139. DOI:10.1186/s12933-018-0782-0.</mixed-citation><mixed-citation xml:lang="en">Liu X, Yang ZG, Gao Y, et al. Left ventricular subclinical myocardial dysfunction in uncomplicated type 2 diabetes mellitus is associated with impaired myocardial perfusion: a contrast-enhanced cardiovascular magnetic resonance study. Cardiovasc Diabetol. 2018;17(1):139. DOI:10.1186/s12933-018-0782-0.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Shivu GN, Phan TT, Abozguia K, et al. Relationship between coronary microvascular dysfunction and cardiac energetics impairment in type 1 diabetes mellitus. Circulation. 2010;121(10):1209-15. DOI:10.1161/CIRCULATIONAHA.109.873273.</mixed-citation><mixed-citation xml:lang="en">Shivu GN, Phan TT, Abozguia K, et al. Relationship between coronary microvascular dysfunction and cardiac energetics impairment in type 1 diabetes mellitus. Circulation. 2010;121(10):1209-15. DOI:10.1161/CIRCULATIONAHA.109.873273.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Ledwidge MT, O’Connell E, Gallagher J, et al. Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (St Vincent’s Screening TO Prevent Heart Failure) study. Eur J Heart Fail. 2015;17(7):672-9. DOI:10.1002/ejhf.286.</mixed-citation><mixed-citation xml:lang="en">Ledwidge MT, O’Connell E, Gallagher J, et al. Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (St Vincent’s Screening TO Prevent Heart Failure) study. Eur J Heart Fail. 2015;17(7):672-9. DOI:10.1002/ejhf.286.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Ihm SH, Youn HJ, Shin DI, et al. Serum carboxy-terminal propeptide of type I procollagen (Pip) is a marker of diastolic dysfunction in patients with early type 2 diabetes mellitus. Int J Cardiol. 2007;122(3):e36-e8. DOI:10.1016/j.ijcard.2007.07.057.</mixed-citation><mixed-citation xml:lang="en">Ihm SH, Youn HJ, Shin DI, et al. Serum carboxy-terminal propeptide of type I procollagen (Pip) is a marker of diastolic dysfunction in patients with early type 2 diabetes mellitus. Int J Cardiol. 2007;122(3):e36-e8. DOI:10.1016/j.ijcard.2007.07.057.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Li Q, Li P, Su J, et al. LncRNA NKILAwas upregulated in diabetic cardiomyopathy with early prediction values. Exp Ther Med. 2019;18(2):1221-5. DOI:10.3892/etm.2019.7671.</mixed-citation><mixed-citation xml:lang="en">Li Q, Li P, Su J, et al. LncRNA NKILAwas upregulated in diabetic cardiomyopathy with early prediction values. Exp Ther Med. 2019;18(2):1221-5. DOI:10.3892/etm.2019.7671.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Галявич А.С., Терещенко С.Н., Ускач Т.М. и др. Хроническая сердечная недостаточность. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(11):6162. DOI:10.15829/1560-4071-2024-6162. EDN: WKIDLJ</mixed-citation><mixed-citation xml:lang="en">Galyavich AS, Tereshchenko SN, Uskach TM, et al. 2024 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2024;29(11):6162. (In Russ.) DOI:10.15829/1560-4071-2024-6162. EDN: WKIDLJ</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Руяткина Л.А., Руяткин Д.С. Многоплановые эффекты метформина у пациентов с сахарным диабетом 2 типа. Сахарный диабет. 2017;20(3):210-9. DOI:10.14341/DM2003458-64.</mixed-citation><mixed-citation xml:lang="en">Ruyatkina LA, Ruyatkin DS. Multidimensional effects of metformin in patients with type 2 diabetes. Diabetes mellitus. 2017;20(3):210-9. (In Russ.) DOI:10.14341/DM2003458-64.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013;6(3):395-402. DOI:10.1161/CIRCHEARTFAILURE.112.000162.</mixed-citation><mixed-citation xml:lang="en">Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013;6(3):395-402. DOI:10.1161/CIRCHEARTFAILURE.112.000162.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Morris A. Diabetes: A new hope for insulin-sensitizing drugs. Nat Rev Endocrinol. 2017;13(12):687. DOI:10.1038/nrendo.2017.150.</mixed-citation><mixed-citation xml:lang="en">Morris A. Diabetes: A new hope for insulin-sensitizing drugs. Nat Rev Endocrinol. 2017;13(12):687. DOI:10.1038/nrendo.2017.150.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Мамедов М.Н., Марданов Б.У., Дудинская Е. Н. Сердечная недостаточность у больных сахарным диабетом: диагностика, лечение, профилактика. М.: Фонд «Кардиопрогресс», 2015.</mixed-citation><mixed-citation xml:lang="en">Mamedov MN, Mardanov BU, Dudinskaya EN. Heart failure patients with diabetes: diagnosis, treatment, prevention. Moscow: Fond “Kardioprogress”, 2015 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Ussher JR, Baggio LL, Campbell JE, et al. Inactivation of the cardiomyocyte glucagonlike peptide-1 receptor (GLP-1R) unmasks cardiomyocyteindependent GLP-1R-mediated cardioprotection. Mol Metab. 2014;3(5):507-17. DOI:10.1016/j.molmet.2014.04.009.</mixed-citation><mixed-citation xml:lang="en">Ussher JR, Baggio LL, Campbell JE, et al. Inactivation of the cardiomyocyte glucagonlike peptide-1 receptor (GLP-1R) unmasks cardiomyocyteindependent GLP-1R-mediated cardioprotection. Mol Metab. 2014;3(5):507-17. DOI:10.1016/j.molmet.2014.04.009.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-22. DOI:10.1056/NEJMoa1603827.</mixed-citation><mixed-citation xml:lang="en">Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-22. DOI:10.1056/NEJMoa1603827.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761-72. DOI:10.1038/s41569-020-0406-8.</mixed-citation><mixed-citation xml:lang="en">Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761-72. DOI:10.1038/s41569-020-0406-8.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Sattar N, McLaren J, Kristensen SL, et al. SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia. 2016;59(7):1333-9. DOI:10.1007/s00125-016-3987-3.</mixed-citation><mixed-citation xml:lang="en">Sattar N, McLaren J, Kristensen SL, et al. SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia. 2016;59(7):1333-9. DOI:10.1007/s00125-016-3987-3.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Connelly KA, Mazer CD, Puar P, et al. Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial. Circulation. 2023;147(4):284-95. DOI:10.1161/CIRCULATIONAHA.122.062769.</mixed-citation><mixed-citation xml:lang="en">Connelly KA, Mazer CD, Puar P, et al. Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial. Circulation. 2023;147(4):284-95. DOI:10.1161/CIRCULATIONAHA.122.062769.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Sato T, Aizawa Y, Yuasa S, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol. 2018;17(1):6. DOI:10.1186/s12933-017-0658-8.</mixed-citation><mixed-citation xml:lang="en">Sato T, Aizawa Y, Yuasa S, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol. 2018;17(1):6. DOI:10.1186/s12933-017-0658-8.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Soucek F, Covassin N, Singh P, et al. Effects of atorvastatin (80 mg) therapy on quantity of epicardial adipose tissue in patients undergoing pulmonary vein isolation for atrial fibrillation. Am J Cardiol. 2015;116(9):1443-6. DOI:10.1016/j.amjcard.2015.07.067.</mixed-citation><mixed-citation xml:lang="en">Soucek F, Covassin N, Singh P, et al. Effects of atorvastatin (80 mg) therapy on quantity of epicardial adipose tissue in patients undergoing pulmonary vein isolation for atrial fibrillation. Am J Cardiol. 2015;116(9):1443-6. DOI:10.1016/j.amjcard.2015.07.067.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
